AzTrials
AzTrials

Total Hip Arthroplasty (THA)REVISENCT07053943

Infection-related Revision Rates After Single-dose Versus Multiple-dose Antibiotic Prophylaxis in Primary Hip and Knee Arthroplasty: a Comparative Implementation Study.

An observational study of Total Hip Arthroplasty (THA) and Antibiotic Prophylaxis, run by JointResearch at 1 site in Netherlands.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

Prosthetic Joint Infection (PJI) is a significant issue in joint replacement surgeries, causing additional surgeries and substantial healthcare costs. An effective way of preventing these infections is through the use of antibiotics before and after surgery. Read more about this study

Who is it for?
Any age
How many people
70,000 participants
Where
1 siteNetherlands
Study dates
1 Jun 2025to May 2027
How long will I take part?
2 Years
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: All patients undergoing Total Hip Arthroplasty and Total Knee Arthroplasty

Who may be able to join

  • Patients undergoing primary Total Hip Arthroplasty or primary Total Knee Arthroplasty

Who cannot join

  • Patients undergoing Revision Hip Arthroplasty or Revision Knee arhtroplasty

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Netherlands1 site
  • OLVG Hospital

    Amsterdam, North Holland, 1091AC

Other trials in Netherlands

About this study

Official title: Revision Rate Due to Infection With Single-dose Versus Multiple-dose Antibiotic Prophylaxis During Primary Hip- and Knee Arthroplasty: A Hybrid Effectiveness Implementation Target Trial Emulation Study.

Prosthetic Joint Infection (PJI) is a significant issue in joint replacement surgeries, causing additional surgeries and substantial healthcare costs. An effective way of preventing these infections is through the use of antibiotics before and after surgery. However, there is ongoing debate regarding the optimal dosage regimen for these antibiotics to achieve maximum effectiveness. In the Netherlands, most hospitals currently give multiple doses of antibiotics for hip and knee replacement surgeries. A new upcoming guideline recommends using only one dose of antibiotics, which could have several benefits. It might reduce the need for antibiotics overall, decrease the work for nurses, and shorten hospital stays. However, it is unclear if this change is safe or effective.

This study aims to compare the effectiveness of the current multi-dose antibiotic method with the new single-dose approach. We will also look at how well hospitals adopt this new guideline (implementation) and compare the healthcare costs associated with both antibiotic regimens. By studying real-world data from surgeries and patient records, we want to determine if the single-dose strategy is as effective at preventing infections and reducing the need for additional surgeries.

Read the detailed description

SUMMARY Rationale: Antibiotic Stewardship (AS) is focusing on the precise use of antibiotics to enhance patient outcomes and curb antibiotic resistance. This concept is especially pertinent in the context of Prosthetic Joint Infection (PJI), a primary cause for revision hip arthroplasty (RHA) and revision knee arthroplasty (RKA). While perioperative antibiotic prophylaxis has proven to significantly reduce PJI risk, the optimal duration-whether to administer a single dose or multiple doses-remains hotly debated. When reflecting on the administration practices, a 2018 national survey indicated that 90% of Dutch hospitals utilized multi-dose antibiotic prophylaxis during total hip arthroplasty (THA) and total knee arthroplasty (TKA). The Federation for Medical Specialisten (FMS) reviewed the perioperative antibiotic prophylaxis guideline to more strongly endorse single-dose prophylaxis. By evaluating implementation effectiveness following the updated guideline and assessing the broader implications on healthcare costs, this study seeks to deliver insights that could shape future antibiotic use in orthopaedic surgery, ultimately influencing policies and practices in the Netherlands and beyond.

Objective: The objectives of the study are as follows:

  1. Assess the implementation-effectiveness of the single-dose implementation strategy following the new guideline's introduction by assessing the percentage of hospitals that adopt to the new guideline and the time these hospitals take to do so.
  2. Compare the rate of revision procedures due to infection between single-dose and multiple-dose antibiotic prophylaxis during THA and TKA by comparing the relative amount of revisions surgeries due to infection one year before implementation of the new guideline and one year after implementation of the new guideline.
  3. Compare the healthcare costs between single-dose and multi-dose perioperative antibiotic prophylaxis by estimating the cost per antibiotic dose and the costs related to the extended hospital admission.

Study design: A novel hybrid, non-inferiority, de-implementation effectiveness target trial emulation study using real-world data is proposed to complete the study objectives:

  1. A survey will be sent to orthopaedic surgeons from Dutch institutions performing THA and TKA. The questions relate to their current antibiotic policy and their intention to adopt to the new guideline. Institutions that comply with the current guideline and intent to adopt the new guideline within the next year will be included. The included Institutions will be actively monitored to determine the successfulness of the implementation of the single-dose prophylaxis strategy.
  2. Data from the Dutch arthroplasty register (LROI) will be used to document the relative amount of revision procedures due to infection for all included institutions. The relative amount of revision procedures for infection will be compared between the year before adoption to the new guideline and the year after.
  3. Innovative search software (CTcue) will be employed to retrieve individual patient data from electronic patient records for all patients who underwent THA or TKA in the observation period. 4. 4. The data from the LROI register (institution level) will be compared to the data retrieved from electronic patient records by CTcue (patient level). In this way, we aim to validate the LROI database regarding infection-related revision and give direction to future complementation of the LROI with re-interventions due to PJI.

Study population: All patients who had primary THA or TKA in the included institutions will be followed up for 12 months until the end of the observation period (June 2027) or until the date of revision for infection, revisions for other indication, death or end of follow-up.

Main study parameters/endpoints: Related to the study objectives, the main study endpoints are as follows:

  1. The percentage of hospitals that adopt to the new guideline and the time these hospitals take to do so.
  2. The relative amount of revisions surgeries due to infection reported in the LROI and retrieved with CTcue, compared in the periode one year before implementation of the new guideline and one year after implementation of the new guideline.
  3. The cost per antibiotic dose and the costs related to the extended hospital admission, compared between single-dose and multi-dose perioperative antibiotic prophylaxis.
Keywords
Antibiotic Prophylaxis, Total Knee Arthroplasty, Total hip Arthroplasty, revision Arthroplasty

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07053943
Study groupRoleWhat they receive
Single-dose antibiotic prophylaxis in Total Hip ArthroplastyAll patients undergoing Total Hip Arthroplasty before the guideline advocating for a multiple dose antibiotic regime.
Single-dose antibiotic prophylaxis in Total Knee ArthroplastyAll patients undergoing Total Knee Arthroplasty before the guideline advocating for a multiple dose antibiotic regime.
Multi-dose antibiotic prophylaxis in Total Hip ArthroplastyAll patients undergoing Total Hip Arthroplasty after the guideline advocating for a multiple dose antibiotic regime.
Multi-dose antibiotic prophylaxis in Total Knee ArthroplastyAll patients undergoing Total Hip Arthroplasty after the guideline advocating for a multiple dose antibiotic regime.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The percentage of hospitals that adopt to the new guideline and the time these hospitals take to do so.

    Measured: 2 years

  2. The relative amount of revisions surgeries due to infection reported in the LROI and retrieved with CTcue, compared in the periode one year before implementation of the new guideline and one year after implementation of the new guideline.

    Measured: 2 years

  3. The cost per antibiotic dose and the costs related to the extended hospital admission, compared between single-dose and multi-dose perioperative antibiotic prophylaxis.

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Jul 2025
  2. Study start1 Jun 2025
  3. Primary completionDec 2026 (estimated)
  4. Study completionMay 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
70,000 participants (estimated)
Target duration
2 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT07053943
Sponsor's protocol ID
WO 25.069
Acronym
REVISE
Status last verified
Jul 2025
First submitted
23 Jun 2025
Last updated
8 Jul 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Total Hip Arthroplasty (THA) and Antibiotic Prophylaxis, run by JointResearch at 1 site in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 8 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The percentage of hospitals that adopt to the new guideline and the time these hospitals take to do so. (time frame: 2 years). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in